Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Clarus Ventures, LLC (CIK 1431431) reported $425.5M across 10 reported positions in its SEC 13F filing for 2018-09-30. Largest positions: TECX ($153.7M, 36.11%), NSTG ($72.0M, 16.91%), SIENQ ($65.2M, 15.33%), FTSV ($56.9M, 13.38%), GRTS ($36.6M, 8.59%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | TECX | AvroBio Inc. | $153.7M | 36.11% | 3.0M | Hold |
| 2 | NSTG | Nanostring Technologies Inc. | $72.0M | 16.91% | 4.0M | Added |
| 3 | SIENQ | Sientra Inc. | $65.2M | 15.33% | 2.7M | Hold |
| 4 | FTSV | Forty Seven Inc | $56.9M | 13.38% | 3.8M | Hold |
| 5 | GRTS | Gritstone Oncology Inc | $36.6M | 8.59% | 2.6M | New |
| 6 | ETTX | Entasis Therapeutics Holdings Inc | $17.7M | 4.15% | 1.6M | New |
| 7 | VERO | Restoration Robotics Inc. | $10.4M | 2.43% | 3.6M | Hold |
| 8 | VBIV | VBI Vaccines Inc. | $6.5M | 1.53% | 2.7M | Hold |
| 9 | EPIX | ESSA Pharma Inc. | $5.0M | 1.18% | 1.7M | Hold |
| 10 | ATXS | Catabasis Pharmaceuticals Inc. | $1.6M | 0.38% | 2.0M | Hold |
Source: SEC Form 13F filings · as of 2018-09-30